DrugPatentWatch Database Preview
Drugs in Development Information for Bococizumab
» See Plans and Pricing
What is the drug development status for Bococizumab?
Bococizumab is an investigational drug.
There have been 10 clinical trials for Bococizumab.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.
The most common disease conditions in clinical trials are Hyperlipidemias, Dyslipidemias, and Cardiovascular Diseases. The leading clinical trial sponsors are Pfizer, University of California, San Francisco, and San Francisco General Hospital.
There are seven US patents protecting this investigational drug and sixty-four international patents.
Summary for Bococizumab
| US Patents | 7 |
| International Patents | 64 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2013-10-01) |
| Vendors | 0 |
Recent Clinical Trials for Bococizumab
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects | Pfizer | Phase 3 |
| Bococizumab HIV Evaluation (B-HIVE) Study | Pfizer | Phase 3 |
| Bococizumab HIV Evaluation (B-HIVE) Study | San Francisco General Hospital | Phase 3 |
Clinical Trial Summary for Bococizumab
Top disease conditions for Bococizumab
Top clinical trial sponsors for Bococizumab
US Patents for Bococizumab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bococizumab | Start Trial | Peptide-mediated delivery of immunoglobulins across the blood-brain barrier | Mayo Foundation for Medical Education and Research (Rochester, MN) | Start Trial |
| Bococizumab | Start Trial | Antigen-binding proteins that activate the leptin receptor | REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) | Start Trial |
| Bococizumab | Start Trial | Cholestosome vesicles for incorporation of molecules into chylomicrons | THERASYN SENSORS, INC. (Eggertsville, NY) | Start Trial |
| Bococizumab | Start Trial | Treatment with anti-PCSK9 antibodies | Pfizer Inc. (New York, NY) | Start Trial |
| Bococizumab | Start Trial | Binding-triggered transcriptional switches and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| Bococizumab | Start Trial | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | Incube Labs, LLC (San Jose, CA) | Start Trial |
| Bococizumab | Start Trial | Cell culture medium | LA JOLLA BIOLOGICS, INC. (San Diego, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bococizumab
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bococizumab | Argentina | AR106319 | 2035-10-12 | Start Trial |
| Bococizumab | Australia | AU2016338851 | 2035-10-12 | Start Trial |
| Bococizumab | Brazil | BR112018007318 | 2035-10-12 | Start Trial |
| Bococizumab | Canada | CA3000215 | 2035-10-12 | Start Trial |
| Bococizumab | Chile | CL2018000946 | 2035-10-12 | Start Trial |
| Bococizumab | Chile | CL2019001434 | 2035-10-12 | Start Trial |
| Bococizumab | China | CN108368177 | 2035-10-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
